[verwijderd] 8 juni 2009 15:07 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Voorbeurs: $ 1.43 hoog, want.....8:33AM Keryx Biopharma announces positive Phase 2 data for Zerenex (KERX) 1.20 : Co announces results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on thrice weekly hemodialysis. The study was a multicenter, open-label clinical trial, which enrolled 55 patients. The top line efficacy and safety results from this Phase 2 study were submitted to the FDA, and discussed at a recent face to face meeting with the Division of Cardiovascular and Renal Drug Products. The FDA also reviewed the final reports for the 90-day rat and 16-week canine toxicology studies. The FDA indicated that the results of the Phase 2 study and the toxicology studies were adequate to support entry into a Phase 3 program. Keryx is in the process of finalizing the Phase 3 program in consultation with the FDA. Co says "The promising safety and efficacy profile of Zerenex indicates that there is significant market potential for the drug in the phosphate binder space Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 17 juni 2009 15:30 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 NEW YORK, June 17 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX - News) announced today that the Company has received a letter from The NASDAQ Stock Market confirming that it has regained compliance with the minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2) and that the matter is now closed. The Company also received a letter from the NASDAQ Listing Qualifications Hearings Panel confirming that it has demonstrated a market value of listed securities over the required minimum of $35 million for 10 consecutive trading days, for continued listing on The NASDAQ Capital Market under Listing Rule 5550(b)(2), and that the Panel has determined to continue the listing of the Company's securities on The NASDAQ Stock Market.The Company's stock continues to be listed on the NASDAQ Capital Market and its ticker symbol of KERX remains unchanged."We are pleased to have regained compliance with all the NASDAQ Capital Market listing requirements," stated Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals. "We believe this represents an important step in building value for our stockholders." Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 23 juli 2009 17:57 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Is de weg naar boven hier teug ingezet?Toch al terug boven $1 belandt.Real-Time: 1.09 Up 0.07 (+6.86%) Day's Range: 1.06 - 1.19www.pr-inside.com/keryx-biopharmaceut...finviz.com/screener.ashx?v=341&f=ind_...Tussendoor even deze site meegeven.www.equitytrader.com/graph/default.ph...Mvg,Skip Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 3 augustus 2009 15:21 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:skippy44 schreef:Is de weg naar boven hier teug ingezet?Toch al terug boven $1 belandt.Real-Time: 1.09 Up 0.07 (+6.86%) Day's Range: 1.06 - 1.19www.pr-inside.com/keryx-biopharmaceut...finviz.com/screener.ashx?v=341&f=ind_...Tussendoor even deze site meegeven.www.equitytrader.com/graph/default.ph...Mvg,Skip Voorbeurs:Pre-market Real-Time: 1.70 Up 0.55 (+47.83%)FEATURESMarket Coverage Market Overview Market Update In Play® Story Stocks Short Stories Tech StocksMarket Events Earnings Calendar Economic Calendar Splits Calendar Conference Call Calendar IPO Calendar Upgrades/DowngradesMarket Statistics Market Digest U.S. Market Indices World Market Indices Currency Exchange RatesInPlay8:56AM American Intl: Moody's downgrades Ilfc to Baa3, continues to review (AIG) 13.14 : Moody's Investors Service downgraded the ratings of International Lease Finance (senior unsecured to Baa3 from Baa2, short-term to Prime-3 from Prime-2) and placed the ratings on review for further possible downgrade. The ratings downgrade reflects Moody's view that there is increased uncertainty regarding ILFC's long-term strategy for funding its $44 billion portfolio of commercial aircraft, assuming that the firm's planned divestiture by parent AIG is completed. ILFC has historically relied on access to the unsecured debt markets to meet much of its funding need, enabled by its solid operating performance and also by the implicit and demonstrated support of AIG. Unsecured bonds, notes and bank debt comprised 87% ($27.6 billion) of ILFC's total debt at the end of March. In recent quarters, a combination of factors has severely constrained ILFC's ability to issue new unsecured debt, including credit market contractions, the travails of AIG, and the ongoing efforts by AIG to sell ILFC. Though a sale of ILFC would eliminate the last two of these factors, Moody's believes that ILFC's future access to unsecured debt sources will likely be significantly diminished, notwithstanding a recovery in the debt markets and a transfer of company ownership.8:52AM Fitch affirms Spain at 'AAA'; outlook stable : Fitch Ratings has today affirmed the Kingdom of Spain's (Spain) Long-term foreign and local currency Issuer Default Ratings (IDRs) at 'AAA' respectively. The Outlooks on both ratings are Stable. At the same time, the agency has affirmed Spain's Short-term foreign currency IDR at 'F1+' and the Country Ceiling at 'AAA'. "The rating affirmation and stable outlook are underpinned by the authorities' robust response to the global financial crisis, the resilience of Spain's larger, systemically important banks and ambitious medium term fiscal consolidation targets, including planned cuts in public expenditure from 2010," said Andres Klaar, Associate Director in Fitch's Sovereign group. "Relatively low public debt in the run up to the financial crisis means that over the downturn Spain can still absorb a very substantial fiscal shock while remaining less indebted than its large 'AAA' rating peers in Western Europe. Spain's track record in debt reduction suggests that the authorities will pursue medium-term fiscal consolidation rigorously, even if the target of reducing the deficit to 3% by 2012 may be unrealistic," Klaar added.8:46AM Marathon Oil beats by $0.05, beats on revs (MRO) 32.25 : Reports Q2 (Jun) earnings of $0.58 per share, $0.05 better than the First Call consensus of $0.53; revenues fell 39.8% year/year to $13.36 bln vs the $11.11 bln consensus. "Marathon's businesses performed very well in the second quarter. Our Exploration and Production segment achieved a 12 percent year-over-year increase in production available for sale from continuing operations while our Refining, Marketing and Transportation segment out-performed its competitors in the domestic market posting positive financial results, up slightly from both first quarter and prior year. A continued focus on high mechanical reliability and cost control contributed to our overall solid operating performance. And, in spite of challenging global economic conditions, Marathon continues to maintain a very solid financial position, aided by the value captured from selective asset sales."8:39AM On The Wires : Cantel Medical (CMN) announces that through its Mar Cor Purification subsidiary, has continued the expansion of its water purification and filtration segment by purchasing the assets of Los Angeles-based G.E.M. Water Systems Int'l. The acquired business had pre-acquisition revenues of approximately $3.5 mln. This cash deal is expected to be slightly accretive to Cantel's earnings per share in the first year... AEterna Zentaris (AEZ) announces that Keryx Biopharmaceuticals (KERX) its partner and licensee for perifosine in the North American market, has reached an agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design of a Phase 3 trial for the Company's PI3K/Akt pathway inhibitor compound, perifosine, in relapsed or relapsed/refractory multiple myeloma patients previously treated with bortezomib.8:36AM MGM Mirage reports wider than expected loss, reports revs in-line (MGM) 7.23 : Reports Q2 (Jun) loss of $0.15 per share, $0.06 worse than the First Call consensus of ($0.09); revenues fell 21.2% year/year to $1.49 bln vs the $1.49 bln consensus. The ($0.15) EPS figure excludes non-cash impairment charges of $188 mln, or $0.34 per diluted share net of tax, primarily related to the co's investment in a convertible note, and losses on the retirement of long-term debt of $58 mln primarily related to the redemption of senior debentures required to permit the co's recent secured note issuances - an impact of $0.11 per diluted share net of tax. Las Vegas Strip REVPAR decreased 31%; Casino revenue decreased 12%, mainly as a result of lower table games volume at the Company's Las Vegas Strip resorts; "Perhaps as important, we saw a more stabilized - though still difficult - operating environment in the second quarter. Our operating teams are focused on continuing to sequentially increase cash flow and our CityCenter team is driving towards completion and opening of CityCenter. We believe CityCenter will invigorate the Las Vegas market and be a key component of the future growth of MGM MIRAGE... While we expect the business and convention market to remain challenging in the near term, we are seeing signs of improvement in future bookings and believe we are increasing our market share by offering a superior product and proven best-in-class customer service."8:36AM National Retail Properties beats by $0.05, beats on revs; updates FY09 FFO guidance (NNN) 19.71 : Reports Q2 (Jun) funds from operations of $0.45 per share, $0.05 better than the First Call consensus of $0.40; revenues rose 4.1% year/year to $58.7 mln vs the $55.4 mln consensus. Co issues in-line guidance for FY09, sees FFO of $1.65-1.70 vs. $1.66 consensus, prior guidance $1.65-1.75.8:34AM Apple says Eric Schmidt resigns from its Board of Directors (AAPL) 163.39 : Co announces that Dr. Eric Schmidt, chief executive officer of Google (GOOG), is resigning from Apple's Board of Directors, a position he has held since August 2006. "Unfortun Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 14 september 2009 15:01 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Pre Market:$1.60 0.27 +20.30% Keryx Biopharmaceuticals' (KERX) Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cance.September 14, 2009 8:38 AM EDTKeryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.Dr. Thomas E. Hutson, Director of the Genitourinary Oncology Program at Baylor-Sammons Cancer Center in Dallas, TX, will present Phase 2 results demonstrating perifosine's single agent efficacy in patients with metastatic renal cell carcinoma on Saturday, September 26th at 10:00 am CST, in a presentation entitled " Phase 2 study of perifosine in patients with metastatic renal cell carcinoma progressing after prior therapy with both a VEGF Receptor Inhibitor and an mTOR inhibitor."finance.aol.com/quotes/keryx-biopharm...finviz.com/screener.ashx?v=341&f=ind_...GR, Skip Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 16 september 2009 17:13 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Blijkbaar wordt die hier niet meer gevolgd.Ze zullen het maar weten.Real-Time: $2.26 Up 0.70 (+44.87%) UPDATE 1-Keryx cancer drug gets orphan drug status; shares soarWed Sep 16, 2009 10:48am EDT* Says multiple myeloma drug gets orphan drug status* Says late-stage trial to start by year-end* Keryx shares up as much as 72 pct * Shares of Aeterna Zentaris up as much as 36 pct Sept 16 (Reuters) - Keryx Biopharmaceuticals Inc (KERX.O: Quote, Profile, Research, Stock Buzz) said its experimental cancer drug, KRX-0401, received orphan drug designation from U.S. health regulators, sending its shares up to a new 52-week high.Keryx shares touched a high of $2.63, making them one of the top percentage gainers on Nasdaq, while shares of its Canadian partner Aeterna Zentaris Inc (AEZS.O: Quote, Profile, Research, Stock Buzz) (AEZ.TO: Quote, Profile, Research, Stock Buzz) reached a high of C$1.52 on the Toronto Stock Exchange.The U.S. Food and Drug Administration's orphan drug status is reserved for new therapies that are being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States and grants the drug developers seven years of market exclusivity."The disease (multiple myeloma) based on available clinical data is absolutely the most attractive target market for that drug," Douglas Loe, an analyst at Versant Partners in Toronto said.KRX-0401, which is being tested as a treatment for a type of cancer called multiple myeloma affecting the plasma cells in blood, was in-licensed by Keryx from Aeterna in the United States, Canada and Mexico, while Aeterna retains rights for the rest of the world.Keryx expects the late-stage study of the drug, also called perifosine, to start by the end of the year.Shares of Keryx were trading up 78 cents at $2.34, while shares of partner Aeterna were up 25 percent at C$1.40 on the Toronto Stock Exchange. (Reporting by Vidya L Nathan in Bangalore, with additional reporting by Scott Anderson in Toronto; Editing by Aradhana Aravindan) finviz.com/screener.ashx?v=341&f=ind_...Gr, Skip Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 16 september 2009 18:45 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Ik heb ze gekocht aan 0,20 en heb 1/4e van mijn aandelen verkocht. Ze maken volgende week resultaten bekend van hun phase 2 en zouden dit jaar nog met phase 3 beginnen. Hou ze nog een jaartje of drie denk ik. Heb juist PSDV bijgekocht met de winst, zie hier een kans op verdubbeling of meer tegen het einde van het jaar. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 16:18 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Goed nieuws hier;www.prnewswire.com/news-releases/kery...Kan wel eens snel gaan met de koers van Kerx. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 16:58 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 ik heb gekocht op $3 Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 16:58 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 gaat uitbreken hier 3,08 Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 17:26 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Ziet er goed uit. Ik heb ook gekocht voor $ 3.00 Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 17:29 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:domus muris schreef:Ziet er goed uit. Ik heb ook gekocht voor $ 3.00Ik heb weer verkocht @ 3,07.Zitten onwijs veel mensen tegen te werken. Maar ik kom zeker op korte termijn terug, wellicht vandaag nog. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 18:19 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 doji hier.. doji op een top is erg oppassen voor topvorming Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 20:32 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 koers word steeds flink geblokt.nu weer dik blok op 3,01. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 20:34 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 bied loopt op nu, denk dat deze zo gaat. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 20:46 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:rac69 schreef:koers word steeds flink geblokt.nu weer dik blok op 3,01.3,03 er door heen nu. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 20:49 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 gaat die.3,08 Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 21:13 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:Eisenga schreef:[quote=domus muris]Ziet er goed uit. Ik heb ook gekocht voor $ 3.00[/quote]Ik heb weer verkocht @ 3,07.Zitten onwijs veel mensen tegen te werken. Maar ik kom zeker op korte termijn terug, wellicht vandaag nog.klopt helemaal, liggen er veel dwars hier.3,03 Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 21:28 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 ziet er toch naar uit dat die door schiet zo.bied word steeds groter.rt 3,10 Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 december 2009 21:36 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Dit is een goudmijn waar steeds nieuwe aders in ondekt worden. Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.